Abstract: HSV-1 amplicon vectors efficiently transduce cultured antigen-presenting cells (APC), including both human and murine dendritic cells as well as primary human chronic lymphocytic leukemia (CLL) B cells. Helper-free amplicons have been shown to be especially well-suited for this purpose, since they do not impair the antigen-presenting functions of these target cells. In vivo, amplicon vectors have been used in preclinical studies aimed at the development of therapeutic cancer vaccines, as well as vaccines for Alzheimer's disease, and selected microbial pathogens. Studies in small animal model systems have shown that ex vivo transduction of irradiated tumor cells with amplicon vectors encoding immunomodulatory cytokines such as IL-2 or GM-CSF can elicit protective responses against a tumor challenge. In an experimental model for cancer immunotherapy, direct transduction of preformed tumors with vectors encoding CD40L resulted in slowed tumor growth or tumor eradication. Other studies have examined the ability of amplicons to elicit immune responses against encoded antigens, and have shown that strong cellular immune responses can be generated against amplicon encoded HIV-1 antigens in mice. Thus, amplicon vectors have shown significant promise as vaccine vectors in a range of settings. These promising initial findings highlight the need to perform additional studies, including experiments to evaluate the immunogenicity of amplicon vectors in additional animal models, possibly including nonhuman primates. Overall, amplicon vectors offer compelling advantages when compared to other vaccine-delivery platforms, which include the capacity to incorporate a very large transgene payload and the potential to efficiently transduce mucosal surfaces. It will be important to design future studies to directly test and exploit these features of the amplicon system. The next few years therefore promise to be an exciting and important period in the development of amplicons as vaccine vectors.
I. IMMUNE RESPONSES TO HSV-1 INFECTION
Infection by herpes simplex virus type-1 (HSV-1) typically occurs via mucosal surfaces, and results in the generation of both innate and adaptive immune responses, which control and contain subsequent virus replication in most healthy individuals [Roizman et al., 2001; Taylor et al., 2002; Whitley, 2001] . The virus elicits both humoral and cellular immunity, and both arms of the adaptive immune response appear to be important in containing the extent of initial virus infection of neurons and/or virus reactivation. For example, Mikloska and coworkers showed that neutralizing antibodies prevent the spread of the virus -thereby limiting lesion size and neuronal infection [Mikloska et al., 1999] . In addition, the virus elicits high levels of functionally active, antigen-specific CD4+ and CD8+ T cells [Koelle et al., 2003] . Thus, wild-type HSV-1 is a potent immunogen that is capable of eliciting a strong host immune response.
As is the case for many other viruses, HSV-1 has evolved a number of strategies that allow it to evade host immunity. Johnson and colleagues showed that the immediate early gene product, ICP47, can downregulate MHC class I molecules from the surface of infected cells, and thereby protect virus-infected cells from recognition by antigen-specific CD8+ cytotoxic T-cells [York et al., 1994] . ICP47 directly interacts with the transporter associated with antigen proc-*Address correspondence to this author at the Department of Microbiology and Immunology, 601 Elmwood Avenue, Box 672, Rochester, NY 14642, USA; Tel: (585) Fax: (585) 473-2361; E-mail: stephen_dewhurst@urmc.rochester.edu # These authors contributed equally to this review article essing (TAP), blocking its peptide binding site and thereby inhibiting peptide translocation into the endoplasmic reticulum (ER) [Tomazin et al., 1996] . The product of the UL41 gene, the vhs protein, also contributes to viral evasion of class-I restricted immune responses [Geiss et al., 2000; Samady et al., 2003; Tigges et al., 1996] , and it has been recognized recently that HSV-1 can disrupt MHC class II loading [Neumann et al., 2003] .
The ability of HSV-1 to evade cellular immune responses is matched by its ability to avoid humoral attack. Viral envelope glycoproteins that are expressed both on the virion surface and on the outside of virus-infected cells serve both as functional IgG Fc receptors that sequester host antibodies and prevent antibody-dependent cellular cytotoxicity (gEgI), and as inhibitors of complement activation (gC) [Baucke et al., 1979; Dubin et al., 1990; Dubin et al., 1991; Johnson et al., 1988; McNearney et al., 1987; Para et al., 1980] . The presence of gC on the virion surface also allows HSV-1 virions to resist complement-mediated destruction/neutralization [Judson et al., 2003; Lubinski et al., 2002; Lubinski et al., 1998 ] -which may contribute to the ability of amplicon vectors to mediate effective gene transfer even in the face of pre-existing host immunity (as is discussed later in this review).
Overall, wild type HSV-1 infection results in a potent host immune response that the virus can evade through a variety of mechanisms. Amplicon vectors offer the potential to retain the strong inherent immunogenicity of the parental virus, while eliminating many undesirable viral immune evasion functions -such as class I downregulation.
II. INTERACTION OF HSV-1 WITH DENDRITIC CELLS
One likely reason that HSV-1 elicits a strong host immune response, despite its impressive array of immunoevasion genes, is that the virus can directly infect dendritic cells (DC). These specialized antigen-presenting cells play a central role in the induction and maintenance of host immune responses, and the virus has evolved a number of mechanisms to subvert their function and/or maturation. Viral receptors on DC include heparan sulfate proteoglycans, herpesvirus entry mediator (HVEM) and LIGHT [homologous to LT, inducible expression, competes with herpes simplex virus (HSV) glycoprotein D for HSV entry mediator (HVEM), a receptor expressed on T lymphocytes] [Pollara et al., 2005; Schneider et al., 2004; Spear, 2004] , as well as lectin-binding receptors such as the mannose receptor [Milone et al., 1998 ]. Both LIGHT and HVEM are emerging as important regulators of T cell activation and function [Schneider et al., 2004; Sedy et al., 2005; Wang et al., 2005] , and their engagement by HSV-1 virions results in the activation of NFκB-dependent signaling pathways that regulate DC maturation [Pollara et al., 2005] .
Both immature and mature DC express the receptors that are necessary to mediate entry of HSV-1 [Salio et al., 1999] . However, viral replication is supported only by immature DC [Mikloska et al., 2001] ; mature DC do not appear to support the generation of infectious virions [Kruse et al., 2000] . HSV-1 can inhibit the maturation of immature DC [Salio et al., 1999] , and when mature DC are infected with the virus, their T-cell-stimulatory capacity is diminished and cell surface expression of CD83 is reduced, as a consequence of viral gene expression [Kruse et al., 2000] . However, this remains a somewhat controversial and evolving field. Other investigators have noted that both HSV-1 infected and uninfected bystander myeloid DC become phenotypically more mature, and have suggested that virus infection may trigger release of type I interferon and paracrine activation of bystander DC [Pollara et al., 2004; Pollara et al., 2003] . One possible reason for the complexity of these data may relate to the considerable heterogeneity of DC subpopulations. Thus, HSV-1 appears not to perturb the functional activity of plasmacytoid DC, at least in mice [Yoneyama et al., 2005] .
Overall, there is strong evidence that HSV-1 virions can engage stimulatory receptors present on the surface of DC (LIGHT, HVEM) and transduce intracellular signaling events that exert a powerful effect on DC maturation and function. One of the goals of amplicon-based vaccine approaches is to preserve these desirable signaling properties, while eliminating undesirable activities such as virallymediated cytolysis, downregulation of CD83 and prevention of DC maturation. This may be possible because amplicon vectors do not express any virally-encoded genes. Indeed, deletion of the gene encoding virion host shutoff (vhs) protein prevents HSV-1 mediated inactivation of antigen presentation by DC . This may explain, in part, why deletion of vhs improves the immunogenicity of a candidate replication-defective HSV-1 vaccine strain [Geiss et al., 2000] .
III. INTERACTION OF AMPLICON VECTORS WITH DC AND OTHER APC
The ability of HSV-1 amplicon vectors to transduce antigen-presenting cells (APC), including DC, has been documented in a number of studies. Willis et al., were the first to establish that dendritic cells can be efficiently transduced by HSV-1 amplicon vectors, and to show that this does not result in any loss of maturation or inhibition of T cell stimulatory function [Willis et al., 2001] . By using helper-free HSV-1 amplicon vectors encoding eGFP these workers showed that approximately 70% of bone marrow-derived murine DC were transduced in their cell culture system, and that amplicon-mediated transduction of immature DC resulted in the up-regulation of MHC class II molecules and costimulatory molecules CD80 and CD86 -consistent with partial maturation and activation of the cells. Furthermore, the functional ability of amplicon-transduced DC to stimulate naïve T cells was examined in a mixed lymphocyte reaction (MLR), and found to be unaltered [Willis et al., 2001] .
Broadly similar findings were reported by Nunez and colleagues [Nunez et al., 2004] , and by Gorantla et al. [Gorantla et al., 2005] , who transduced immature murine (Nunez) or human (Gorantla) DC ex vivo with helper free HSV-1 amplicons. Both groups demonstrated efficient expression of model antigens (lacZ, GFP or HIV-1 gp120) by the transduced DC. Nunez also showed that the transduced murine DC retained their ability to stimulate naïve T cells in a MLR [Nunez et al., 2004] , while Gorantla used flow cytometric analysis to demonstrate a partial phenotypic maturation of amplicon-transduced human DC (as reflected by up-regulation of HLA-DR, CD80, CD86 and CD83 when compared to untreated DC). Moreover, when vectortransduced human DC were introduced into non-obese diabetic severe combined immunodeficient (NOD/SCID) mice reconstituted with autologous human peripheral lymphocytes (huPBL-NOD/SCID mice), HIV-1 antigen-specific humoral and cellular immune responses were elicited [Gorantla et al., 2005] . In contrast, Nunez and colleagues reported that the injection of amplicon-transduced murine DC into syngeneic mice resulted in the generation of strong humoral responses against a vector-encoded transgene (lacZ) or against structural components of the amplicon particle (HSV-1 gB), in the absence of a detectable cytotoxic responses against either antigen [Nunez et al., 2004] . The failure to elicit antigenspecific CTL in this study is rather surprising, and it is discordant with the results reported by both Willis and Gorantla. It is possible that subtle differences in the dendritic cell populations or culture conditions used, or the choice of the exogenous antigen (lacZ versus PSA or HIV-1 gp120) may have contributed to these results.
The interaction of amplicon vectors with other APC has also been explored. Tolba et al., used HSV amplicon vectors to transduce primary human chronic lymphocytic leukemia B cells (CLL cells) [Tolba et al., 2001] , and found that both helper-containing and helper-free vector stocks were capable of transducing CLL targets. However, when CLL B cells were transduced with CD40L (CD154)-or B7.1 (CD80)-encoding amplicon stocks that were packaged with a standard helper virus (the HSV strain 17-derived IE3 deletion mutant virus, D30EBA), the cells showed a diminished ability to function as T cell stimulators, when compared to cultures that were transduced with matched, helper-free amplicon stocks [Tolba et al., 2001] . The authors concluded that helper-free amplicon stocks may be advantageous for immunotherapy or vaccine applications, possibly because of their reduced cytotoxicity and/or lack of expression of viral immunoevasion genes.
Follow up studies by the same group showed that helperfree HSV-1 amplicons encoding LIGHT also enhanced the antigen presenting capacity of CLL cells, albeit to a lesser degree than hf-HSV-CD40L amplicons . Helper-free amplicons have also been used to express antigens in primary human peripheral blood mononuclear cells (PBMC). This has allowed the convenient generation of autologous target cells for use in short-term, single cell assays that can directly quantitate the frequency of antigenspecific cytotoxic T cells in human subjects [Snyder et al., 2003] .
Collectively, these studies show that helper-free HSV amplicons can efficiently transduce myeloid DC and other APCs, without impairing their antigen-presenting function. This has important implications for the use of amplicon vectors for vaccine delivery.
IV. USE OF AMPLICONS FOR CANCER VACCI-NATION AND IMMUNOTHERAPY
There is considerable interest in the use of amplicon vectors for the development of cancer vaccines or immunotherapies, and a number of preclinical studies have established proof-of-principle data that establish the feasibility of this approach. These studies can be broadly segregated into those that have utilized amplicon stocks that contained helper-virus and those that did not (helper-free stocks). Since efficient systems for the generation of high titer, helper-free amplicon stocks have become available only in the past few years Fraefel et al., 1996; Saeki et al., 2001; Saeki et al., 1998; Stavropoulos et al., 1998; Sun et al., 2000; Sun et al., 1999; Tang et al., 2001; Yang et al., 2001 ], many of the initial studies used helper-containing stocks. For historical reasons, we will consider these studies first.
The first study that used amplicon vectors for cancer vaccination was published by Yuman Fong and his colleagues, in 1996 [Tung et al., 1996] . This study used helpercontaining amplicon stocks to express interleukin (IL)-2 in murine hepatoma cells (HEPA 1-6) and in human hepatobiliary tumor specimens; mice that were immunized with the irradiated, HSV-IL-2 transduced HEPA 1-6 cells developed tumor-specific cytotoxic T lymphocyte (CTL) activity and were also protected against tumor challenge [Tung et al., 1996] . This promising initial result was followed by other studies that used amplicon vectors to express immunomodulatory cytokines in order to elicit tumor-specific immune responses, including experiments that used IL-2 [Mizuno et al., 2000] , IL-12 [Jarnagin et al., 2000; Karpoff et al., 2000] or GM-CSF [Herrlinger et al., 2000; Karpoff et al., 1997] , as well as various chemokines [Kutubuddin et al., 1999; and costimulatory ligands, such as ICAM-1 (CD54) [D'Angelica et al., 1999] , B7.1 (CD80) and CD40L (CD154) [Kutubuddin et al., 1999; Tolba et al., 2001; .
In one set of experiments, rats were immunized with irradiated hepatoma cells that were transduced with amplicon particles encoding lacZ, IL-2 or GM-CSF and then challenged 21 days later by intrasplenic inoculation of live tumor cells. GM-CSF and IL-2 encoding amplicon vaccines were found to reduce tumor burden in the animals, and when the amplicon treatment was combined with interferon-gamma, a number of the animals completely eliminated their tumor [Karpoff et al., 1997] . In another experimental model system, amplicon vectors encoding the chemokine RANTES or the T-cell costimulatory ligand B7.1 (CD80) were evaluated for their ability to eradicate a pre-established lymphoma in C57/BL6 mice. In this case, mice were inoculated subcutaneously with 1 x 10 6 viable EL4 murine T-lymphoma cells and once the tumors reached a predefined size (5-6 mm), they were directly inoculated with amplicon vectors (2 x 10 6 pfu/injection). Complete tumor regression was observed in 17/26 (65%) of mice injected with the B7.1-encoding amplicon and in 11/22 (50%) of mice injected with RANTESencoding vector; when the two vectors were combined, the tumor regression rate rose to 88% (23 of 26 mice) [Kutubuddin et al., 1999] .
Other combined immunotherapeutic regimens for cancer treatment have also been explored. For example, Tolba and colleagues directly injected pre-existing tumors with 3.5 x 10 6 helper-virus containing amplicon particles encoding lacZ, CD40L or the secondary lymphoid tissue chemokine (SLC) . In these studies, two types of tumors were pre-established in BALB/c mice -A20 (B cell lymphomas) or CT-26 (adenocarcinoma). In the A20 tumor model, 4/5 mice treated with HSV-SLC eradicated their tumors and 5/6 mice treated with HSV-CD40L did so; this result was determined to be statistically significant when compared to HSV-lacZ treated controls (p<0.05). In the CT26 tumor model, the tumors were not eradicated by amplicon treatment, but their growth was slowed to a statistically significant degree . However, treatment of mice with a mixture of amplicon particles encoding both CD40L and SLC had no additional protective effect. Thus, in this case, the combination regimen failed to demonstrate enhanced effectiveness. However, in other experimental model systems, such as a hepatic metastatic model system using syngeneic CT-26 colorectal tumor cells in BALB/c mice, multiagent combinations (RANTES/ B7.1/GM-CSF) have been shown to exhibit superior antitumor efficacy when compared to single-agent regimens [Delman et al., 2002] .
A novel approach to combination (immuno)therapy relates to the use of amplicon vectors that encode immunomodulatory gene products, in conjunction with oncolytic HSV-1 viruses [Carew et al., 2001] . This offers the potential to develop a single recombinant virus preparation that has two modes of action -oncolysis and vaccination [Carew et al., 2001] . In one set of experiments, the replicationcompetent oncolytic HSV-1 strain G207 was used as a helper virus to package amplicon vectors encoding IL-2 (HSV-IL-2), or else it was coadministered with IL-2 encoding amplicon particles that had been generated using a stan-dard helper virus (the IE3-deleted, D30EBA strain) [Zager et al., 2001] . When high doses of virus were used in either a rat hepatoma model or a mouse syngeneic carcinoma model, HSV-IL2 or G207 were, individually, highly effective in reducing tumor burden. However, when a low dose of virus was used in the murine model system, the anti-tumor response was suboptimal and could be substantially improved by coadministration of G207 and HSV-IL2, or by using G207 to package the HSV-IL2 amplicon [Zager et al., 2001] . Similar findings were obtained in a different experimental animal model, in which syngeneic flank tumors (SCC VII cells) were established in C3HeJ mice, and then injected with the same virus preparations. In this case, the combination approaches again showed superior anti-tumor activity, when compared to either G207 or HSV-IL2 alone [Carew et al., 2001] .
While helper-containing amplicons are being used in increasingly creative ways in the preclinical setting, there are relatively few studies to date that have reported on the use of helper-free amplicons for cancer vaccination or immunotherapy. In one study, Willis and colleagues transduced murine DC ex vivo with hf-amplicons encoding human prostatespecific antigen and showed that subcutaneous immunization of mice with the transduced DC resulted in a PSA-specific CTL response. In this study, mice were also immunized twice with HSV-1 amplicon transduced DC, and then challenged i.m. 3 weeks later, with a PSA-expressing tumor cell line (CT26-PSA). At doses of 10 4 and 2 x 10 3 tumor cells, all mice (5/5 per group) remained tumor-free, while at a challenge dose of 10 5 cells, 3 of 5 mice showed no tumor growth and the remaining two animals had slowed tumor growthwith eventual outgrowth of a PSA-negative tumor in one case [Willis et al., 2001] . This protection was antigenspecific, since PSA-negative tumors (CT26-neo) grew at all doses.
A recent study by Zibert and colleagues also used helperfree amplicons, and compared their effectiveness with that of matched helper-containing amplicons in the setting of acute lymphoblastic leukemia (ALL) [Zibert et al., 2005] . In these studies, amplicon vectors encoding either IL-2 or the costimulatory ligand CD70 were constructed, and then packaged using either a helper-free system or a helper virus (the IE3 deleted recombinant virus, d120). Equally high rates of gene transfer in primary ALL cells were obtained using both amplicon stocks, and the stocks were then evaluated for antitumor activity in BALB/cBYJ mice bearing syngeneic tumors (A20 cells). In these experiments, the vaccine formulation consisted of irradiated A20 cells that had been transduced with amplicon stocks in vitro, and which were then administrated s.c. to the mice. Vaccine cells expressing both IL-2 and CD70 significantly inhibited lymphoblastic tumor growth; the helper-free and helper-containing stocks were equally effective [Zibert et al., 2005] . Interestingly, when helper-containing amplicon stocks were used for the vaccine preparation, an equivalent level of protection was also obtained with an "empty" amplicon vector (lacking IL-2 or CD70). This effect was not seen with helper-free amplicon stocks, and suggests that -at least under some circumstances -the presence of helper-virus in amplicon stocks may be desirable, perhaps because of the cytotoxic and/or proinflammatory effects of the helper virus [Olschowka et al., 2003 ].
The effect of helper virus on amplicon-induced immune responses, particularly in the context of vaccination, is likely to be complex. Potentially desirable pro-inflammatory qualities of the helper virus may be balanced by less desirable effects on antigen presenting cells, as noted by Tolba [Tolba et al., 2001] . Thus, more studies of helper free-amplicon stocks are needed in the cancer setting, as well as additional analyses that directly compare the effectiveness of helpercontaining versus helper-free amplicon stocks are needed. It will also be important to determine how the use of minimally cytotoxic helper viruses [Johnson et al., 1992; Johnson et al., 1994; Krisky et al., 1998; Lilley et al., 2001; Wu et al., 1996] , or novel production methods that allow the virtual elimination of helper virus [Logvinoff et al., 2001; Zaupa et al., 2003] , will impact upon the effectiveness of helpercontaining amplicons.
V. USE OF AMPLICONS FOR IMMUNIZATION AGAINST MICROBIAL PATHOGENS
To date, most amplicon-based vaccination studies have focused on tumor immunotherapy, but there is also considerable interest in the use of amplicons for immunization against microbial/viral pathogens and neurologic disease.
Tsitoura and colleagues constructed and tested helperdependent amplicons encoding Hepatis C virus (HCV) surface glycoproteins, E1 and E2, which are considered to be candidate vaccine antigens [Tsitoura et al., 2002] . The E1E2 and E2 coding sequences were expressed under the control of the HSV-1 IE4 (α22/α27) promoter, and were fused with the HSV-1 gE signal peptide to ensure effective protein secretion. Protein expression was then evaluated in a panel of cultured cell lines; results showed that most of the expressed HCV E1 and E2 glycoproteins formed misfolded aggregates, although substantial amounts of non-aggregated products were also detected, which exhibited the size, glycosylation pattern and subcellular localization expected for authentic HCV E1 and E2 [Tsitoura et al., 2002] . Subsequent studies by this group used a replication-defective HSV-1 vector deleted in gH (a disabled infectious single-cycle [DISC] vector) to express HCV E2, from the CMV immediate-early promoter [Lucas et al., 2003] . This resulted in the generation of glycoprotein products that were mostly non-aggregated, and able to bind to CD81 (as expected for authentic HCV E2). Intraperitoneal delivery of this vector also elicited a humoral immune response to HCV E2 in mice, which was largely of the IgG2a isotype -consistent with a Th1-type response [Lucas et al., 2003] . No direct comparison of E2 expression by amplicon-versus DISC-vectors containing matched inserts was performed, and immune responses to amplicon-vectored HCV glycoproteins were not analyzed. Hence, these studies leave unresolved the question as to whether amplicon vectors might have specific advantages in terms of antigen expression or elicitation of immune responses, when compared to replication-defective HSV-1 vectors.
Studies on immune responses to amplicon-vectored viral antigens have been performed by other workers. Our laboratory has shown that a single inoculation of 1x10 6 trans-ducing units of a helper-free amplicon encoding the HIV-1 envelope glycoprotein, gp120, resulted in the induction of strong, antigen-specific cellular and humoral responses in BALB/c mice [Hocknell et al., 2002] . In this analysis, the amplicon-elicited CTL response was highly durable, persisting for at least 5 months. Subsequent work by Wang and colleagues demonstrated that amplicon-induced cellular immune responses could be strongly enhanced by prior priming with either a DNA vaccine encoding the same antigen (heterologous prime-boost), or by an initial amplicon immunization (homologous prime-boost) [Wang et al., 2003 ].
Gorantla and colleagues have taken a slightly different approach, using amplicon-transduced autologous human DC to elicit gp120-specific immune responses in hu-PBL-NOD/SCID mice [Gorantla et al., 2005] . In this case, gp120-specific cellular and humoral immune responses were also elicited, with partial protection from an infectious virus challenge in the immunized mice.
VI. USE OF AMPLICONS FOR IMMUNO-PREVENTION OR IMMUNOTHERAPY OF NEURO-LOGIC DISEASE
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder that is characterized by the loss of neurons and synapses in regions of the brain, as well as by the presence of unusual protein aggregates that include tau-containing neurofibrillary tangles and beta amyloid-containing plaques. It has been suggested that the accumulation of amyloid beta (Aβ) peptides into plaques may be an important cause of the underlying pathology in AD, and as a result, there is considerable interest in developing immunotherapies that might protect against neurodegeneration in AD [Gelinas et al., 2004; Hock et al., 2003; Morgan et al., 2000; Schenk, 2002; Weiner et al., 2002; Weksler et al., 2005; Winblad et al., 2003 ].
Bowers and colleagues have used helper-free amplicons to elicit responses against amyloid beta (Aβ), in a transgenic model for Alzheimer's disease (TG2576 AD mice). In these experiments, two amplicon constructs were used -one encoding Aβ 1-42 alone (HSVA) and the other encoding Aβ 1-42 fused with tetanus toxin fragment C (HSVA-TtxFC) as an adjuvant. Three subcutaneous injections of 1 x 10 6 transducing units of these amplicons, given at monthly intervals, resulted in strong humoral responses to Aβ. Interestingly, the isotype of the antibody was markedly different in animals that received HSVA-TtxFC (IgG1 isotype antibodies, reflective of a Th2 response, predominated in these animals) versus those that received HSVA (in which IgM antibodies were detected initially, switching to the IgA subclass later). Aβ plaque burden was slightly reduced in transgenic animals that received HSVA-TtxFC, but not in animals treated with HSVA. In addition, immunization of transgenic animals with HSVA resulted in a high rate of mortality within 1-2 weeks of the second amplicon immunization -possibly due to the induction of a marked inflammatory response within the brain. This is analogous to prior results with Aβ peptide immunized mice and also with the moderate CNS inflammation that has been detected in some human clinical trial participants who received Aβ vaccines [Furlan et al., 2003; Nicoll et al., 2003] . Collectively, these data suggest that (i) it may be possible to use amplicon vectors as immunotherapeutic agents for neuroinflammatory diseases such as AD and multiple sclerosis (MS) and (ii) that the use of defined molecular adjuvants may facilitate the "shaping" of amplicon-induced immune responses (e.g., towards Th2 responses for autoimmune conditions such as MS, or towards Th1 responses when designing prophylactic vaccines for microbial pathogens).
VII. EFFECT OF PRE-EXISTING IMMUNITY ON AMPLICON-BASED VACCINES
HSV-1 is ubiquitous in the human population and thus antiviral antibodies are present in most adults. It is conceivable that these may interfere with amplicon-mediated vaccination, either by directly neutralizing the infectivity of amplicon particles or else by triggering the rapid clearance of vector-transduced cells.
The effect of pre-existing immunity on HSV-1 mediated gene transfer has been extensively studied using full-length recombinant HSV-1 vectors including oncolytic virus mutants. Herrlinger and colleagues, for example, showed that pre-existing immunity to HSV-1 decreased initial marker gene expression to about 15% of that in nonimmunized animals, when an oncolytic HSV-1 construct was injected via the intracranial route into rats that had been implanted with syngeneic gliomas [Herrlinger et al., 1998 ]. Thus, in this model, pre-existing immunity diminished but did not abolish HSV-1 mediated gene transfer. A study by Kamiyama and colleagues, which involved the subcutaneous or intramuscular injection of a live-attenuated HSV-1 construct in rats, reached a broadly similar conclusion -although in this case, the reduction in gene transfer efficiency in pre-immune animals was much less pronounced (roughly 60% of levels in nonimmune animals) [Kamiyama et al., 2001] . Consistent with this result, pre-existing anti-HSV-1 immunity had no effect on the anti-tumor activity of the multiply-deleted oncolytic virus, G207, in two different strains of mice (A/J and BALB/c) that were implanted with two different syngeneic tumors (CT26 carcinoma and N18 neuroblastoma) [Chahlavi et al., 1999] .
A study that may have greater relevance to vaccination studies was performed by Brockman and colleagues . This experiment showed that cellular and humoral immune responses to a model antigen (E. coli β-galactosidase) encoded by a replication-defective HSV-1 vector (deleted in the gene encoding ICP8) were unaffected by pre-existing immunity in mice, when the vaccine was delivered via the subcutaneous route . In contrast, a more recent study examined immune responses to a different model antigen (ovalbumin; OVA) encoded by a multiply-deleted replication-defective HSV-1 mutant (deleted in the genes encoding ICP4, ICP22, ICP27 and vhs) [Lauterbach et al., 2005] . In this case, HSV-1 seropositive animals generated reduced cellular immune responses and failed to mount an OVA-specific humoral response when immunized via the S.C. route with the multiply-deleted, replication-defective HSV-1 vector [Lauterbach et al., 2005] .
It is difficult to extrapolate from studies using replication-defective or oncolytic HSV-1 mutants to the effect that pre-existing immunity may exert on amplicon vectors. However, there is little direct information on this point. To our knowledge, there has been only one study that had looked at the effects of pre-existing immunity in an HSV-1 amplicon immunization regimen. This study, which was performed by our laboratory, used a heterologous HSV-1 strain (Patton) to generate an anti-HSV-1 immune response in mice that were subsequently immunized, via the subcutaneous route, with helper-free amplicons that had been packaged using a molecularly cloned derivative of HSV-1 strain 17. The mice were shown to have significant titers of ampliconneutralizing antibodies in their sera at the time of immunization, but this resulted in only a relatively modest (40-60%) reduction in the amplicon-induced CD8 + T cell response in these animals [Hocknell et al., 2002] . The findings are also encouraging because amplicon immunizations were performed shortly after the animals had cleared their experimental HSV-1 infection (i.e., when antiviral antibody titers were near peak levels). Thus, these data suggest that preexisting host immunity is unlikely to interfere with the successful use of amplicon-based vaccines.
VIII. FUTURE NEEDS AND CLINICAL TRANS-LATION
Many questions in regards to the effectiveness of HSV-1 amplicon vectors as vaccine delivery systems remain unresolved, and require further investigation. At the preclinical level, it may be instructive to directly compare the immunogenicity of helper-containing and helper-free amplicon stocks in a range of experimental animal model systems, and to also compare responses to those elicited by replicationdefective HSV-1 vectors encoding matched inserts -such as the DISC vector system originally developed by Minson and others [Ali et al., 2002; Assudani et al., 2005; Farrell et al., 1994; McLean et al., 1994] , or the recombinant HSV vaccine strains being studied by Knipe and coworkers [Da Costa et al., 2000; Da Costa et al., 1999; Da Costa et al., 2001; Murphy et al., 2000] . It will also be important to evaluate the immunogenicity of amplicon vectors following mucosal delivery, in light of the natural ability of HSV-1 to infect mucosal surfaces, and to test their ability to elicit immune responses in nonhuman primates -including animals that have pre-existing immunity to HSV-1. Studies of prime-boost immunization regimens that incorporate amplicons and other vaccination modalities (different virus vectors, DNA plasmids, soluble protein antigen) may also be informative.
It may also be of interest to develop and test DC-targeted amplicon vectors for vaccine delivery, either using transcriptional targeting methods or by modification of viral surface glycoproteins so as to selectively redirect amplicon particles to surface receptors present on DC [Grandi et al., 2004; Spear et al., 2003] . Surface modification of virus may also reduce the effectiveness of virus-neutralizing antibodies in HSV-1-immune hosts, thereby making amplicon vectors even less susceptible to the effects of pre-existing immunity. Other approaches that might reduce such effects include the development of new (helper-free) packaging systems based on viruses other than HSV-1, or the derivation of hybrid packaging systems that incorporate surface glycoproteins from other herpesviruses. These options should be feasible in light of the strong sequence conservation of alphaherpesvirus packaging and origin sequences, and previous work showing the functional complementation of packaging and origin functions between different herpesviruses [Chen et al., 1994; Fixman et al., 1995; Inoue et al., 1994; Martin et al., 1994; Spaete et al., 1985; Webster et al., 1995] . Indeed, it is notable that a number of new herpesvirus amplicon vectors have become available in the past few years, based on viruses other than HSV-1 -including CMV, EBV, HHV-6 and HHV-7 [Borenstein et al., 2004; Borst et al., 2003; Mahmood et al., 2005; Muller et al., 2005; Romi et al., 1999; Turner et al., 2002] .
In considering the clinical application of amplicon-based vaccines, it is striking that, to date, no HSV-1 amplicon vector has yet entered human clinical trial. This highlights the importance of resolving production and purification issues, and of developing methods to generate reproducible vector stocks -particularly when using helper virus to propagate amplicon vectors. It may be possible to use the Cre/loxP system developed by Epstein and colleagues to control the ratio of helper virus to amplicon in such helperdependent systems [Logvinoff et al., 2001; Zaupa et al., 2003] . Alternatively, it may be possible to proceed with initial studies of helper-containing amplicon stocks by using well-characterized, attenuated HSV-1 mutants as helper viruses. Several such mutants, such as G207, NV1020 and 1716, have already been shown to be safe in phase I human clinical trials [Benencia et al., 2005; Harrow et al., 2004; Kuruppu et al., 2005; Markert et al., 2000; Varghese et al., 2002] .
Helper-free amplicon stocks have an obvious advantage compared to helper-containing amplicons, in terms of their potential safety profile and the reproducibility of their manufacturing. Production is, however, more complex since the vector stocks cannot be amplified by serial passage in virussusceptible host cells. However, since helper-free amplicon stocks are currently generated by transient transfection methods analogous to those used to produce adenoassociated virus (AAV) vectors or alphavirus replicons, it should be possible to scale-up manufacturing and production methods such that clinical quantities of vector can be produced. Production of high-titer stocks might conceivably be improved by the use of highly transfectable, but non-FDA approved, cell lines -possibly including neoplastic cells [Lewis, 2001; Tatalick et al., 2005] . Thus, careful, early discussion with the FDA and other regulatory bodies may be an important step in moving amplicon vectors closer to the clinic. In addition, it will be important to derive efficient, GMP-compatible purification methods that result in high recovery of infectious amplicon particles free of residual host cell DNA and protein, such as chromatographic purification methods [Jiang et al., 2004; O'Keeffe et al., 1999] . This could conceivably be facilitated by the use of amplicon vectors that contain a suitable marker or purification tag [Grandi et al., 2004; Jiang et al., 2004] .
IX. SUMMARY AND CONCLUSIONS
HSV-1 amplicon vectors have shown significant promise as vaccine delivery vehicles and/or immunomodulatory agents in a range of preclinical systems, including experimental animal models for cancer treatment and for prophy-lactic immunization against infectious pathogens (notably, HIV-1). It is likely that the broad applicability of amplicon vectors derives in part from the flexibility of the amplicon platform, broad host cell tropism of HSV-1, and the large transgene capacity of the vector system -an asset that remains to be fully exploited in the vaccination setting. The next few years should prove an exciting time in amplicon research, and may set the stage for the first human clinical trials of amplicon-based vaccines.
